Welcome to BioSeeker Group!

Triple Analysis: Colorectal Cancer, Antibodies and Peptides

Additional Information

Published Date Jan 7, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4430
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Colorectal Cancer, Antibodies and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Colorectal Cancer and by the two compound strategies of Antibodies and Peptides.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Antibodies and Peptides.

    To find out more about Triple Analysis: Colorectal Cancer, Antibodies and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Antibodies and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Colorectal Cancer and by the two compound strategies of Antibodies and Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer
The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part II: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Colorectal Cancer
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451
7 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699
8 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039
10 Disclaimer 1040
11 Drug Index 1041
12 Company Index 1050
Figures: Includes 6 Figures
Tables: Includes 242 Tables
Total Number of Pages: 1,056

Part II: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
10 Disclaimer 2361
Figures: Includes 7 Figures
Tables: Includes 355 Tables
Total Number of Pages: 2,361

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
7TM Pharma
A&G Pharmaceutical
Abbott
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adherex
AEterna Zentaris
Affibody
Affimed Therapeutics
Affitech
Affymax
Agenus
AGY Therapeutics
Aida Pharmaceuticals
Aileron Therapeutics
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Algeta
Allos Therapeutics
Allostera
Allosterix
Alnylam
AlphaVax
Alseres Pharmaceuticals
ALSP
Altor BioScience
Ambrilia Biopharma
Amgen
Amorfix Life Sciences
Anavex Life Sciences
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
Antisense Pharma
Antisoma
Aphios
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Apotex
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Ardana
Areva
arGEN-X
Ariad
ArQule
Array BioPharma
Astellas
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Baxter International
Bayer
Berkeley Lab
Betapharma
BioAlliance Pharma
Biocompatibles
Biocon
Biogen Idec
BioInvent
Biokine Therapeutics
Biolex
BioLineRx
BioNumerik
Biosceptre
Biotecnol
Biotest
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Camurus
Can-Fite BioPharma
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celecure
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Cellmid
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Centrose
CG Therapeutics
ChemGenex Pharmaceuticals
Chemokine Therapeutics
Chiasma
Choongwae
Circadian Technologies
Clavis Pharma
Cleveland BioLabs
Clinuvel
Compugen
Cosmo Pharmaceuticals
CSL
CuraGen
Curaxis
CureTech
Curis
Customized Therapeutics
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Debiopharm
Deciphera Pharmaceuticals
Dendreon
DiaMedica
Digna Biotech
Dompe
Dongkook Pharm
Dr Reddy’s
Dyax
Dynavax Technologies
EGEN Inc
Eisai
Elan
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Ergon Pharmaceuticals
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
FasTrack Pharmaceuticals
Favrille
Femta Pharmaceuticals
FibroGen
Five Prime Therapeutics
Formula Pharmaceuticals
Fusion Antibodies
Galaxy Biotech
Galena Biopharma
GammaCan
Ganymed Pharmaceuticals
Gene Techno Science
Genencor
Genentech
Generex
Genmab
Genomic Systems
GENova Biotherapeutics
Genovax
GenPat77
Genta
GenVec
Genzyme
Gilead Sciences
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
Glycotope
GP Pharm
Gradalis
Green Cross
Gryphon Therapeutics
Hawthorn Pharmaceuticals
Heidelberg Pharma
Hoffmann-La Roche
Human Genome Sciences
Idera Pharmaceuticals
IDM Pharma
IkerChem
ImClone Systems
IMED
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunotope
ImmuPharma
Immutep
Incyte Corporation
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insys Therapeutics
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
ISU ABXIS
Ivy Medical Chemicals
Jennerex Biotherapeutics
Johnson & Johnson
KAEL-GemVax
Kaketsuken
KaloBios
Karyon-CTT
Kiadis
Kirax
Kirin Pharma
Kissei
Kyowa Hakko Kirin
Kyto Biopharma
Labopharm
Lee’s Pharmaceutical
Leo
LFB Biotechnologies
LG Life Sciences
Lorus Therapeutics
MacroGenics
Marillion Pharmaceuticals
MAT Biopharma
MBiotec
Meda
Medarex
MediGene
MedImmune
Mediolanum
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
MolMed
Mologen
Mycenax
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nerviano Medical Sciences
Neuren
Neurobiological Technologies
NicOx
Nidus Laboratories
NIH
Nippon Kayaku
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
Novartis
NPS Pharmaceuticals
Nycomed Pharma
OncoGenex Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncozyme Pharma
Onyvax
Orca Therapeutics
Orchestra Therapeutics
Oxford BioMedica
OXiGENE
Paladin Labs
Panacea
PanaGin
PanGenetics
Patrys
Pepscan Therapeutics
Peptagen
PepTx
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
Pharmaclon
PharmaGap
PharmaMar
Pharmexa
Philogen
Pierre Fabre
Plexxikon
POZEN
Prima Biomed
Pro-Pharmaceuticals
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progenics Pharmaceuticals
Protagonist
Protherics
Q Chip
QLT
Ramot
Raptor Pharmaceutical
Recepta biopharma
Receptor BioLogix
Regeneron
Rigel
Sanofi
Sanofi-Aventis
Santaris Pharma
Sarepta Therapeutics
Sareum
SBI Biotech
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Serometrix
Shanghai CP Guojian
Shenogen
Shire
Sigma-Tau
Simcere Pharmaceuticals
Soligenix
Spectrum Pharmaceuticals
Spirogen
SRI International
Stainwei Biotech
Sunol Molecular
SuperGen
SuppreMol
Supratek Pharma
Switch Pharma
Symphogen
Synageva BioPharma
SynDevRx
SynerGene Therapeutics
Synta Pharmaceuticals
Tactic Pharma
Taiho
Takeda
Talon Therapeutics
Tamir Biotechnology
Targa Therapeutics
Targepeutics
Tau Therapeutics
Taxolog
TeGenero
Telik
Teva
Thallion Pharmaceuticals
The Genetics Company
Therion Biologics
Theryte
ThromboGenics
Titan Pharmaceuticals
Tolerx
TopoTarget
Tracon Pharmaceuticals
Transgene
Trillium Therapeutics
Trion Pharma
UCB
Unigene
United Biomedical
United Therapeutics
Vaccinex
Wakunaga
VasGene Therapeutics
Vaxil BioTherapeutics
Vaxon Biotech
Vertex Pharmaceuticals
Vical
Wilex
VioQuest Pharmaceuticals
Viragen
Viralytics
Viventia Biotech
Wyeth
XBiotech
Xencor
Xerion
Xigen
Xoma
Y’s Therapeutics
Yakult Honsha
YM BioSciences
Zelos Therapeutics
Zenotech
Zensun
A Shortlist of Drugs Included are:
131I-tositumomab
A6
abagovomab
abarelix
ABT-510
adecatumumab
AEZS-108
afamelanotide
aflibercept
AGS-1C4D4
ALD-518
alemtuzumab
amatuximab
AME-133
AMG-386
angiopep+paclitaxel
Angiozyme
AV-299
belimumab
bevacizumab
BHQ880
blinatumomab
BMS-663513
BMS-936558
brentuximab vedotin
brivanib alaninate
BT-062
capecitabine
carlumab
catumaxomab
CBP-501
CDX-1307
CDX-1401
cediranib
cetuximab
cixutumumab
CMAB302
CMAB304
conatumumab
corticorelin acetate
CT-011
dalotuzumab
daratumumab
denosumab
deslorelin
doxifluridine
E-75
elotuzumab
EMD-273063
EMD525797
emepepimut-S
EP-100
epratuzumab
epratuzumab-Y90
ertumaxomab
everolimus
farletuzumab
figitumumab
FPI-01
fresolimumab
galiximab
ganitumab
gemtuzumab ozogamicin
girentuximab
glembatumumab vedotin
goserelin
GS-6634
GV-1001
GX-301
Her-2/Neu peptides
histrelin
I-131-labetuzumab
ibritumomab tiuxetan
icrucumab
imMucin
inotuzumab ozogamicin
interferon gamma
intetumumab
IPH-2102
ipilimumab
IPP-204106
iratumumab
irinotecan bead
irinotecan hydrochloride
ISA-P53-01
kahalalide F
L19-TNFalpha
lanreotide
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
lintuzumab
LIP-131I
lorvotuzumab mertansine
lucatumumab
lumiliximab
LY2495655
lymphomun
MABp1
mapatumumab
MCS-110
MDX-1379
MEDI-551
MEDI-573
MGN-1703
milatuzumab
milatuzumab-doxorubicin
MM-111
MM-121
mogamulizumab
MOR202
MOR208
MORAb-004
moxetumomab pasudotox
NAFB001
naptumomab estafenatox
natalizumab
necitumumab
netupitant
nimotuzumab
obinutuzumab
octreotide
octreotide, LAR
ofatumumab
olaratumab
onartuzumab
Onyvax-105
oregovomab
OTS-102
ozarelix
panitumumab
pasireotide
pasireotide LAR
PAT-SC1
perifosine
pertuzumab
PF-4856884
plitidepsin
polyclonal antibody stimulator
raltitrexed
ramucirumab
Reditux
regorafenib
RG-7160
rilotumumab
rindopepimut
rituximab
robatumumab
romiplostim
romurtide
samalizumab
SAR-3419
siltuximab
sotatercept
Survivac
Sym-004
tegafur + uracil
tegafur + uracil + leucovorin
Tenarad
thymalfasin
tigatuzumab
TM-30339
tocilizumab
TRC-105
tremelimumab
TRU-016
TS-1
tucotuzumab celmoleukin
U3-1287
Ublituximab
vapreotide, immediate-release
veltuzumab
vitespen
volociximab
VX-001
yttrium Y 90 clivatuzumab tetraxetan
zalutumumab
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Antibodies and Peptides.
    To find out more about Triple Analysis: Colorectal Cancer, Antibodies and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Antibodies and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Breast Cancer, Colorectal Cancer and Antibodies
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Colorectal Cancer and by the compound strategy of Antibodies. Learn More


Triple Analysis: Lung Cancer, Melanoma and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Melanoma and by the mechanism/target/effect of Cancer Vaccines. Learn More

Other selected research from the 'Oncology' category:


Lymphoma: Analytical Tool
This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of lymphoma. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface. Learn More


Colorectal Cancer Drug Pathway Analyzer
There are today at least 516 targeted molecular therapies known to affect more than 252 specific intracellular signaling pathways for the treatment of colorectal cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 313 drug targets that are included in this drug-pathway analyzing tool. No less than 301 of these have been recorded with mutations and 60 drug targets have mutations which have been causally implicated in cancer. Learn More